Walvax Biotechnology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	7.2yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO

Walvax Biotechnology has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hua Zhou	Chief Financial Officer	10.4yrs	CN¥3.41m	0.048% CN¥ 11.0m
Yun Yan Wu	Director of Operations	7.1yrs	CN¥1.85m	0.042% CN¥ 9.7m
Jin Long Zhao	Chief Investment Officer	7.1yrs	CN¥1.87m	no data
Lin Yuan	Technical Director	7.3yrs	CN¥2.61m	no data
Wei Yao	Marketing Director	8.3yrs	CN¥2.53m	no data
Qing Gongsun	Director of Human Resources	7.3yrs	CN¥1.77m	0.050% CN¥ 11.6m
Jiankang Zhang	VP & Director	no data	CN¥2.38m	no data
Shao Zhong Dong	VP & Director	no data	CN¥2.53m	no data
Yu Ran Liu	Board Secretary	2.1yrs	CN¥1.46m	no data
Qingtang Duan	Engineering Director	1.3yrs	CN¥1.38m	no data
Changxiong Wu	Accounting Supervisor	no data	no data	no data

7.2yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 300142's management team is seasoned and experienced (7.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jiankang Zhang	VP & Director	4.5yrs	CN¥2.38m	no data
Shao Zhong Dong	VP & Director	2.8yrs	CN¥2.53m	no data
Yunchun Li	Chairman	15.4yrs	CN¥4.33m	1.7% CN¥ 392.0m
Zhen Huang	Vice Chairman	7.5yrs	CN¥5.56m	1.11% CN¥ 255.6m
Jianmei Zhao	Independent Director	4.3yrs	CN¥114.60k	no data
Shiqing Ding	Chairwoman of the Supervisory Board	4.3yrs	no data	no data
Yongwu Fan	Non-Independent Director	4.3yrs	CN¥83.70k	no data
Ting Yan	Director	3yrs	CN¥333.40k	0.0044% CN¥ 1.0m
Jinyu Zhu	Independent Director	2.1yrs	CN¥114.60k	no data
Ganghong Sun	Independent Director	2.1yrs	CN¥114.60k	no data
Lingbing Zeng	Independent Director	2.1yrs	CN¥114.60k	no data
Geng Yun	Employee Supervisor	2.1yrs	no data	no data

3.6yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 300142's board of directors are considered experienced (3.6 years average tenure).

Walvax Biotechnology Management

Management criteria checks 2/4

Key information

Recent management updates

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.054 (vs CN¥0.061 in 3Q 2023)

New minor risk - Share price stability

Walvax Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.18 in 2Q 2023)

Walvax Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

First quarter 2024 earnings released: EPS: CN¥0.009 (vs CN¥0.11 in 1Q 2023)

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.46 in FY 2022)

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment deteriorates as stock falls 16%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.073 in 3Q 2022)

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.24 in 2Q 2022)

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Full year 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.27 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.073 (vs CN¥0.029 in 3Q 2021)

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.021 in 1Q 2021)

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥50.88

Earnings released

New 90-day high - CN¥91.80

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age